Published in J Am Coll Cardiol on April 17, 2006
Brugada syndrome. Pacing Clin Electrophysiol (2006) 2.61
Prolonged Tpeak-to-tend interval on the resting ECG is associated with increased risk of sudden cardiac death. Circ Arrhythm Electrophysiol (2011) 2.35
Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. Am J Physiol Heart Circ Physiol (2007) 2.28
Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis. Circulation (2016) 1.49
Potential pro-arrhythmic effect of cardiac resynchronization therapy. J Saudi Heart Assoc (2013) 1.26
Does Tpeak-Tend provide an index of transmural dispersion of repolarization? Heart Rhythm (2007) 1.23
Cellular basis for the repolarization waves of the ECG. Ann N Y Acad Sci (2006) 1.19
J-wave syndromes: Brugada and early repolarization syndromes. Heart Rhythm (2015) 1.14
Brugada syndrome: recent advances and controversies. Curr Cardiol Rep (2008) 0.98
Drug-induced spatial dispersion of repolarization. Cardiol J (2008) 0.94
Electrocardiographic methods for diagnosis and risk stratification in the Brugada syndrome. J Saudi Heart Assoc (2014) 0.91
J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. Heart Rhythm (2016) 0.87
Brugada Syndrome: Clinical, Genetic, Molecular, Cellular, and Ionic Aspects. Curr Probl Cardiol (2015) 0.86
Repolarization parameters are associated with mortality in chagas disease patients in the United States. Indian Pacing Electrophysiol J (2014) 0.85
Sympathetic nerve stimulation, not circulating norepinephrine, modulates T-peak to T-end interval by increasing global dispersion of repolarization. Circ Arrhythm Electrophysiol (2014) 0.85
Diesel exhaust inhalation increases cardiac output, bradyarrhythmias, and parasympathetic tone in aged heart failure-prone rats. Toxicol Sci (2012) 0.83
Evaluation of Electrocardiographic T-peak to T-end Interval in Subjects with Increased Epicardial Fat Tissue Thickness. Arq Bras Cardiol (2015) 0.83
Relationship between mechanical and electrical remodelling in patients with cardiac resynchronization implanted defibrillators. Europace (2011) 0.83
Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice. World J Clin Cases (2015) 0.82
The Association between Myocardial Iron Load and Ventricular Repolarization Parameters in Asymptomatic Beta-Thalassemia Patients. Adv Hematol (2012) 0.82
Surface Electrocardiogram Predictors of Sudden Cardiac Arrest. Ochsner J (2016) 0.82
Normal standards for computer-ECG programs for prognostically and diagnostically important ECG variables derived from a large ethnically diverse female cohort: the Women's Health Initiative (WHI). J Electrocardiol (2013) 0.81
Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes? Cardiovasc Diabetol (2014) 0.81
Arrhythmia risk in liver cirrhosis. World J Hepatol (2015) 0.79
T-peak to T-end abnormality in pediatric patients with syncope. Iran J Pediatr (2012) 0.79
Heart repolarization changes after anthracycline therapy in the children with cancer. Iran J Ped Hematol Oncol (2014) 0.79
Short-term repeatability of electrocardiographic Tpeak-Tend and QT intervals. J Electrocardiol (2014) 0.79
Pathogenesis and management of Brugada syndrome. Nat Rev Cardiol (2016) 0.78
QT Adaptation and Intrinsic QT Variability in Congenital Long QT Syndrome. J Am Heart Assoc (2015) 0.78
Effect of non-dipper and dipper blood pressure patterns on Tp-Te interval and Tp-Te/QT ratio in patients with metabolic syndrome. Int J Clin Exp Med (2014) 0.78
Evaluation of Tp-Te interval and Tp-Te/QTc ratio in patients with coronary artery ectasia. Int J Clin Exp Med (2014) 0.77
The relation between QT interval and T-wave variables in hypertensive patients. J Pharm Bioallied Sci (2011) 0.76
Repolarization Heterogeneity: Beyond the QT Interval. J Am Heart Assoc (2016) 0.76
Risk stratification in electrical cardiomyopathies. Herz (2009) 0.76
Brugada Syndrome: Defining the Risk in Asymptomatic Patients. Arrhythm Electrophysiol Rev (2016) 0.75
Comparison of Tpe Changing on ECG, in Pre and Post Dialysis and Post Transplantation. Nephrourol Mon (2016) 0.75
Acute and Chronic Changes and Predictive Value of Tpeak-Tend for Ventricular Arrhythmia Risk in Cardiac Resynchronization Therapy Patients. Chin Med J (Engl) (2016) 0.75
Brugada Syndrome:Risk Stratification And Management. J Atr Fibrillation (2016) 0.75
The Effects of Metabolic Syndrome on TpTe Interval and TpTe/QT Ratio in Patients with Normal Coronary Arteries. Eurasian J Med (2014) 0.75
Electrocardiographic findings in patients with polycythemia vera. Int J Med Sci (2011) 0.75
Evaluation of Tp-Te Interval and Tp-Te/QT Ratio in Patients with Coronary Slow Flow Tp-Te/QT Ratio and Coronary Slow Flow. Eurasian J Med (2015) 0.75
The influence of type 2 diabetes and gender on ventricular repolarization dispersion in patients with sub-clinic left ventricular diastolic dysfunction. Am J Cardiovasc Dis (2015) 0.75
Assessment of ventricular repolarization inhomogeneity in patients with mitral valve prolapse: value of T wave peak to end interval. Int J Clin Exp Med (2014) 0.75
Assessment of total cardiac repolarization's spatial distribution among patients with aortic sclerosis. Int J Clin Exp Med (2015) 0.75
Evaluation of inhomogeneities of repolarization in patients with psoriasis vulgaris. Arch Med Sci (2016) 0.75
Evaluation of Tp-e interval, Tp-e/QT ratio and Tp-e/QTc ratio in patients with subclinical hypothyroidism. Ther Adv Endocrinol Metab (2017) 0.75
Prognostic value of Tpeak-Tend interval in patients with acute pulmonary embolism. BMC Cardiovasc Disord (2015) 0.75
The effect of renal transplantation on ventricular repolarization in children with chronic renal failure. Int J Organ Transplant Med (2013) 0.75
J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. J Arrhythm (2016) 0.75
Abnormal repolarization in the acute myocardial infarction patients: a frequency-based characterization. Open Biomed Eng J (2014) 0.75
Risk stratification in young patients with channelopathies. Indian Pacing Electrophysiol J (2010) 0.75
Electrophysiological mechanisms of long and short QT syndromes. Int J Cardiol Heart Vasc (2016) 0.75
Exercise-Induced Repolarization Changes in Patients with Isolated Myocardial Bridging. Med Sci Monit (2015) 0.75
Electrocardiographic Markers of Appropriate Implantable Cardioverter-Defibrillator Therapy in Young People with Congenital Heart Diseases. Pediatr Cardiol (2017) 0.75
Low Iron Stores in Otherwise Healthy Children Affect Electrocardiographic Markers of Important Cardiac Events. Pediatr Cardiol (2017) 0.75
Prolonged Tp-e Interval and Tp-e/QT Ratio in Children with Mitral Valve Prolapse. Pediatr Cardiol (2016) 0.75
[Brugada ECG]. Herzschrittmacherther Elektrophysiol (2015) 0.75
[Brugada syndrome]. Herzschrittmacherther Elektrophysiol (2012) 0.75
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 79.76
Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol (1992) 12.18
Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation (2005) 8.76
QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J (1990) 4.28
Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation (1998) 4.13
Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation (2002) 3.76
A single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ Res (2000) 3.68
The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol (1999) 3.57
Natural history of Brugada syndrome: insights for risk stratification and management. Circulation (2002) 3.10
Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families. Circulation (2000) 2.81
Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. Pacing Clin Electrophysiol (1994) 2.21
Cellular basis for complex T waves and arrhythmic activity following combined I(Kr) and I(Ks) block. J Cardiovasc Electrophysiol (2001) 2.14
Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm (2004) 2.07
Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation (2005) 1.94
Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation (2003) 1.92
Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation (2002) 1.91
Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. J Clin Invest (2002) 1.84
Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation (2005) 1.78
T-peak to T-end interval may be a better predictor of high-risk patients with hypertrophic cardiomyopathy associated with a cardiac troponin I mutation than QT dispersion. Clin Cardiol (2002) 1.72
Transmural dispersion of repolarization and ventricular tachyarrhythmias. J Electrocardiol (2004) 1.67
Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction. J Am Coll Cardiol (1995) 1.61
Brugada syndrome: 1992-2002: a historical perspective. J Am Coll Cardiol (2003) 1.54
Brugada syndrome: a decade of progress. Circ Res (2002) 1.54
The Brugada syndrome: diagnostic criteria and cellular mechanisms. Eur Heart J (2001) 1.50
Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing. Circulation (2004) 1.39
T peak-Tend interval as an index of transmural dispersion of repolarization. Eur J Clin Invest (2001) 1.35
Dispersion of ventricular repolarization: reality? Illusion? Significance? Circulation (1998) 1.32
QT-interval prolongation in right precordial leads: an additional electrocardiographic hallmark of Brugada syndrome. J Am Coll Cardiol (2003) 1.16
Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3. Cardiovasc Res (2005) 1.15
Brugada syndrome: from cell to bedside. Curr Probl Cardiol (2005) 1.08
Modulation of transmural repolarization. Ann N Y Acad Sci (2005) 1.07
Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation (2005) 0.91
Measurement of QT dispersion. Heart (1998) 0.80
An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm (2009) 4.99
Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation (2002) 3.76
Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation (2003) 3.68
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation (2007) 2.90
Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm (2010) 2.79
Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation (2003) 2.74
The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol (2010) 2.56
Electromechanical coupling in patients with the short QT syndrome: further insights into the mechanoelectrical hypothesis of the U wave. Heart Rhythm (2007) 2.44
Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol (2008) 2.42
Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med (2008) 2.38
Transient outward current (I(to)) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm (2011) 2.26
Fever-induced Brugada pattern: how common is it and what does it mean? Heart Rhythm (2013) 2.25
Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation (2002) 2.23
The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell (2005) 2.19
Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy. Circ Arrhythm Electrophysiol (2009) 2.16
Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet (2002) 2.16
Transmural heterogeneity of calcium activity and mechanical function in the canine left ventricle. Am J Physiol Heart Circ Physiol (2003) 2.12
Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm (2004) 2.07
Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol (2004) 2.05
Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm (2006) 2.03
Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm (2011) 2.01
A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome. Cardiovasc Res (2008) 2.01
Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci (2003) 1.97
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm (2008) 1.96
Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm (2006) 1.91
Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation (2002) 1.91
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther (2004) 1.88
A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet (2009) 1.87
Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm (2011) 1.87
Short QT syndrome: pharmacological treatment. J Am Coll Cardiol (2004) 1.87
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet (2013) 1.86
Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation (2004) 1.86
Cellular basis for the monophasic action potential. Which electrode is the recording electrode? Cardiovasc Res (2004) 1.85
Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation (2002) 1.84
Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm (2005) 1.83
The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol (2010) 1.78
Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol (2009) 1.78
Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol (2005) 1.74
Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7). Heart Rhythm (2006) 1.74
Phenotypic characterization of a large European family with Brugada syndrome displaying a sudden unexpected death syndrome mutation in SCN5A:. J Cardiovasc Electrophysiol (2004) 1.69
Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm (2008) 1.69
Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome. Eur Heart J (2005) 1.61
Brugada-like syndrome in infancy presenting with rapid ventricular tachycardia and intraventricular conduction delay. Circulation (2011) 1.60
Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol (2006) 1.60
A novel mutation in the HCN4 gene causes symptomatic sinus bradycardia in Moroccan Jews. J Cardiovasc Electrophysiol (2010) 1.60
Early repolarization syndrome: a decade of progress. J Electrocardiol (2013) 1.59
AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog. J Cardiovasc Pharmacol (2010) 1.57
Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm (2006) 1.56
Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations. J Am Coll Cardiol (2011) 1.55
Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect of IKr and IKur/Ito block. Am J Physiol Heart Circ Physiol (2004) 1.53
Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy. Heart Rhythm (2009) 1.51
Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation (2003) 1.51
Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation (2005) 1.50
Functional expression of "cardiac-type" Nav1.5 sodium channel in canine intracardiac ganglia. Heart Rhythm (2006) 1.50
Fever and Brugada syndrome. Pacing Clin Electrophysiol (2002) 1.48
Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant. Heart Rhythm (2012) 1.46
Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm (2008) 1.46
Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. Heart Rhythm (2011) 1.46
Resolving the M-cell debate: why and how. Heart Rhythm (2011) 1.45
Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. Heart Rhythm (2011) 1.44
A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents. Heart Rhythm (2011) 1.43
KCNE2 modulation of Kv4.3 current and its potential role in fatal rhythm disorders. Heart Rhythm (2009) 1.43
Is a narrow and tall QRS complex an ECG marker for sudden death? Heart Rhythm (2008) 1.42
Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing. Circulation (2004) 1.39
Mode of onset of ventricular fibrillation in patients with early repolarization pattern vs. Brugada syndrome. Eur Heart J (2009) 1.38
Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J (2011) 1.37
Autonomic aspects of arrhythmogenesis: the enduring and the new. Curr Opin Cardiol (2004) 1.35
Cellular and subcellular alternans in the canine left ventricle. Am J Physiol Heart Circ Physiol (2007) 1.32
Can inhibition of IKur promote atrial fibrillation? Heart Rhythm (2008) 1.31
Cellular basis for ST-segment changes observed during ischemia. J Electrocardiol (2003) 1.31
Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf (2008) 1.30
Occurrence of "J waves" in 12-lead ECG as a marker of acute ischemia and their cellular basis. Pacing Clin Electrophysiol (2007) 1.28
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol (2010) 1.27
Gain of function in IKs secondary to a mutation in KCNE5 associated with atrial fibrillation. Heart Rhythm (2008) 1.27
New developments in atrial antiarrhythmic drug therapy. Nat Rev Cardiol (2010) 1.27
Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm (2007) 1.27
Does Tpeak-Tend provide an index of transmural dispersion of repolarization? Heart Rhythm (2007) 1.23
Maximum diastolic potential of human induced pluripotent stem cell-derived cardiomyocytes depends critically on I(Kr). PLoS One (2012) 1.23
Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol (2010) 1.21
The role of local voltage potentials in outflow tract ectopy. Europace (2010) 1.20
Atrial-selective sodium channel blockers: do they exist? J Cardiovasc Pharmacol (2008) 1.18
M cells in the human heart. Circ Res (2010) 1.17
Dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation (2006) 1.16
Potential proarrhythmic effects of biventricular pacing. J Am Coll Cardiol (2005) 1.15
Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. Cardiovasc Res (2007) 1.15
Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation (2004) 1.14
Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol (2009) 1.13
Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs (2009) 1.12
Accelerated inactivation of the L-type calcium current due to a mutation in CACNB2b underlies Brugada syndrome. J Mol Cell Cardiol (2009) 1.11
Long QT, syndactyly, joint contractures, stroke and novel CACNA1C mutation: expanding the spectrum of Timothy syndrome. Am J Med Genet A (2011) 1.11
Short QT syndrome. Genotype-phenotype correlations. J Electrocardiol (2005) 1.11
Prominent I(Ks) in epicardium and endocardium contributes to development of transmural dispersion of repolarization but protects against development of early afterdepolarizations. J Cardiovasc Electrophysiol (2002) 1.10
HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. J Cardiovasc Pharmacol (2003) 1.09
Pharmacological approach to the treatment of long and short QT syndromes. Pharmacol Ther (2008) 1.09
The Brugada syndrome: is an implantable cardioverter defibrillator the only therapeutic option? Pacing Clin Electrophysiol (2002) 1.08
Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block. Am J Physiol Heart Circ Physiol (2011) 1.08
Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. Circulation (2006) 1.08
Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry. Heart Rhythm (2008) 1.07